Non‐invasive Prenatal Diagnosis for BRCA Mutations – a Qualitative Pilot Study of Health Professionals’ Views

Bennett, J. E.; Chitty, Lyn S.; Lewis, Colin M.

doi:10.1007/s10897-015-9858-0

Cited by 13 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…57 However, although some urge caution in the use of NIPD to detect BRCA1 and BRCA2 genes in unborn children, other health professionals believe that NIPD offers parents-to-be who already have a disease the guarantee that it will not be passed on to their descendants. 58…”

Section: Rectifying or Altering Our Inheritable Genomementioning

confidence: 99%

Implications of CRISPR-Based Germline Engineering for Cancer Survivors

Katz

Pitts

2017

Ther Innov Regul Sci

View full text Add to dashboard Cite

Cancer survivors can carry germline mutations that will be transmitted to their progeny. Today, many of these mutations have been identified and can be tracked. With the recent development of genome-editing technologies and CRISPR (clustered regularly interspaced short palindromic repeats), the possibility of genetically modifying the human germline-gametes and embryos-has never been closer. This perspective has sparked a controversy within the scientific community with reactions ranging from calls for a ban on germline modification to cautious approval of further research. This Editorial analyzes the possible adoption of CRISPR-based germline engineering to prevent the spread of cancer predispositions in the human population. We discuss whether the genomic edition of human sperm and eggs would contribute to rectifying or altering the heritable genome. We anticipate the emergence of a new form of liberal eugenics fueled by a logic of offer and demand from stakeholders such as cancer survivors and their relatives and offspring, but also from fertility clinics, biotech firms, insurers, and clinicians. From a regulatory perspective, validating the clinical safety and utility of CRISPR-based germline engineering is an essential step. However, with time, gradually perfecting the technology and assessing the economic benefits for stakeholders could soften society's resistance and align opinions in support of genomic decontamination of human germlines. This progressive shift would be justified in the name of cancer prevention as well as a moral obligation to facilitate the conception of cancer-free children at a cost that is acceptable to individuals and health systems.

show abstract

Section: Rectifying or Altering Our Inheritable Genomementioning

confidence: 99%

Implications of CRISPR-Based Germline Engineering for Cancer Survivors

Katz

Pitts

2017

Ther Innov Regul Sci

View full text Add to dashboard Cite

show abstract

“…Moreover, Bennett et al, proposed to use NIPT for detecting BRCA1/2 mutations [32], starting a holistic model of insight into the maternal and fetal genome.…”

Section: Discussionmentioning

confidence: 99%

Is there a future for cell-free fetal dna tests in screening for preeclampsia?

2019

View full text Add to dashboard Cite

CffDNA screening is a powerful diagnostic tool in the prenatal diagnosis algorithm for chromosomal abnormalities. With detailed ultrasound examination as the mainstay of first-trimester risk assessment, cffDNA has been shown to be superior to first-trimester combined screening (FTCS) in false-positive rates for trisomy 21 detection. In light of the growing interest in cffDNA testing and the possibility of it replacing first-trimester biochemistry, we decided to investigate the usefulness of cffDNA tests in early-pregnancy risk assessment for preeclampsia (PE). The aim of this review paper was to evaluate clinical application of first-trimester cfDNA in predicting PE, as well as to investigate its possible use in first-trimester PE screening enhancement, also in cases where biochemistry is not performed.

show abstract

“…Indeed, noninvasive prenatal screening for fetal hemophilia 20 and sickle-cell disease 21 already has been demonstrated, and noninvasive prenatal testing for BRCA mutations is on the horizon. 22 As sequencing costs fall and analytical methods improve, it may become technically feasible to mine previously collected genetic data for carrier status of genes not initially targeted. These potential long-term genetic privacy implications from cell-free DNA screening have prompted the National Council on Disability to call for greater oversight of the use of prenatal genetic information, 23 though the response to this call has been limited.…”

Section: Privacy Concerns In Prenatal Genetic Testingmentioning

confidence: 99%

Privacy Risks in Prenatal Aneuploidy and Carrier Screening

Parobek

Russo

Lewkowitz

2021

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Modern prenatal genetic screening techniques such as cell-free fetal DNA and expanded carrier screening genotype substantial amounts of maternal and fetoplacental DNA. Although DNA can be deidentified by stripping protected health information from genetic data, anonymized DNA can be reidentified using genetic databases, raising long-term genetic privacy concerns for both mother and fetus. In this commentary, we explore the evolution of prenatal genetic screening and how modern screening techniques may pose unanticipated privacy risks. We highlight knowledge gaps and outline steps to improve patient awareness of and control over their genetic privacy, including specific recommendations for laboratories and prenatal care practitioners who offer screening. We also encourage our colleagues who provide prenatal care to be well informed about the privacy implications of the genetic tests we order and to be vocal advocates for our patients' genetic privacy, both with the laboratories that perform these tests and in the public sphere.

show abstract

Non‐invasive Prenatal Diagnosis for BRCA Mutations – a Qualitative Pilot Study of Health Professionals’ Views

Cited by 13 publications

References 34 publications

Implications of CRISPR-Based Germline Engineering for Cancer Survivors

Implications of CRISPR-Based Germline Engineering for Cancer Survivors

Is there a future for cell-free fetal dna tests in screening for preeclampsia?

Privacy Risks in Prenatal Aneuploidy and Carrier Screening

Contact Info

Product

Resources

About